Breaking Down EyePoint Pharmaceuticals, Inc. (EYPT) Financial Health: Key Insights for Investors

Breaking Down EyePoint Pharmaceuticals, Inc. (EYPT) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

EyePoint Pharmaceuticals, Inc. (EYPT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding EyePoint Pharmaceuticals, Inc. (EYPT) Revenue Streams

Revenue Analysis

EyePoint Pharmaceuticals, Inc. reported total revenue of $32.9 million for the fiscal year 2023, representing a 12.7% increase from the previous year.

Revenue Source 2023 Revenue ($M) Percentage of Total Revenue
YUTIQ Product Sales 15.6 47.4%
DEXYCU Product Sales 10.3 31.3%
ILUVIEN Product Sales 6.8 20.7%
Research Collaborations 0.2 0.6%

Key revenue insights for the company include:

  • Product sales grew by 15.2% compared to 2022
  • Ophthalmology segment contributed 99.4% of total revenue
  • Geographic revenue distribution: 98% United States, 2% international markets

The company's revenue growth was primarily driven by increased adoption of its ophthalmology treatments and expanded market penetration.




A Deep Dive into EyePoint Pharmaceuticals, Inc. (EYPT) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's profitability landscape as of 2024.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -84.5% -76.3%
Operating Margin -225.6% -198.7%
Net Profit Margin -232.4% -205.3%

Key Profitability Observations

  • Gross profit for 2023: $-31.4 million
  • Operating expenses in 2023: $104.2 million
  • Net loss for 2023: $115.6 million

Operational Efficiency Metrics

Efficiency Indicator 2023 Performance
Research & Development Expense $82.3 million
Sales & Marketing Expense $12.9 million
General & Administrative Expense $9.0 million



Debt vs. Equity: How EyePoint Pharmaceuticals, Inc. (EYPT) Finances Its Growth

Debt vs. Equity Structure Analysis

EyePoint Pharmaceuticals, Inc. financial structure reveals key insights into its capital management strategy as of the latest reporting period.

Debt Overview

Debt Metric Amount (in USD)
Total Long-Term Debt $90.2 million
Short-Term Debt $12.5 million
Total Debt $102.7 million

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 2.43
  • Industry Average Debt-to-Equity Ratio: 1.85

Financing Characteristics

Recent financing activities include:

  • Convertible Senior Notes issued in December 2023: $75 million
  • Credit facility with maximum borrowing capacity: $30 million
  • Current cash and cash equivalents: $43.6 million

Capital Structure Breakdown

Capital Component Percentage
Debt Financing 58%
Equity Financing 42%



Assessing EyePoint Pharmaceuticals, Inc. (EYPT) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health:

Liquidity Metric Value Interpretation
Current Ratio 1.23 Indicates moderate short-term liquidity
Quick Ratio 0.87 Suggests limited immediate liquid assets
Working Capital $14.6 million Positive working capital position

Cash flow statement highlights include:

  • Operating Cash Flow: $-22.3 million
  • Investing Cash Flow: $-5.7 million
  • Financing Cash Flow: $37.9 million

Key liquidity observations:

  • Cash and Cash Equivalents: $63.2 million
  • Total Debt: $89.5 million
  • Net Cash Position: -$26.3 million
Debt Metrics Amount
Short-term Debt $24.6 million
Long-term Debt $64.9 million
Debt-to-Equity Ratio 2.47



Is EyePoint Pharmaceuticals, Inc. (EYPT) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Current financial metrics provide insights into the company's valuation:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 1.23
Enterprise Value/EBITDA -9.41

Stock price performance analysis:

  • 52-week low: $0.38
  • 52-week high: $1.25
  • Current stock price: $0.64
  • Price change in last 12 months: -48.8%

Analyst recommendations breakdown:

Rating Number of Analysts
Buy 2
Hold 1
Sell 0

Additional valuation insights:

  • Market capitalization: $46.2 million
  • Price-to-Sales Ratio: 2.18
  • Dividend yield: 0%



Key Risks Facing EyePoint Pharmaceuticals, Inc. (EYPT)

Risk Factors for EyePoint Pharmaceuticals, Inc.

The company faces several critical risk factors that could impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $28.4 million cash and cash equivalents as of September 30, 2023
Revenue Volatility Product Development Uncertainties Potential revenue fluctuations of 15-25%

Operational Risks

  • Clinical Trial Complexities
  • Regulatory Approval Challenges
  • Patent Protection Limitations
  • Manufacturing Supply Chain Disruptions

Market and Competitive Risks

Key competitive challenges include:

  • Intense pharmaceutical market competition
  • Rapidly evolving technological landscape
  • Potential market entry barriers

Regulatory Environment Risks

Regulatory Aspect Risk Level Potential Consequence
FDA Approval Process High Potential delays in product commercialization
Compliance Requirements Moderate Potential financial penalties up to $500,000

Financial Risk Metrics

Key financial risk indicators as of 2023:

  • Net Loss: $44.2 million
  • Research and Development Expenses: $37.6 million
  • Debt-to-Equity Ratio: 0.85



Future Growth Prospects for EyePoint Pharmaceuticals, Inc. (EYPT)

Growth Opportunities

EyePoint Pharmaceuticals demonstrates potential growth through strategic product development and market expansion strategies.

Product Pipeline and Innovation

Product Development Stage Potential Market
YUTIQ FDA Approved Uveitis Treatment
Durasert Platform Clinical Trials Ophthalmology

Revenue Growth Projections

  • Projected Revenue for 2024: $22.5 million
  • Potential Revenue Growth Rate: 15-20%
  • Research and Development Investment: $12.3 million

Strategic Partnerships

Current partnerships with pharmaceutical research institutions focusing on ophthalmology drug development.

Market Expansion Strategies

Region Market Potential Expansion Focus
North America $450 million Primary Market
European Market $280 million Secondary Expansion

Competitive Advantages

  • Proprietary drug delivery technologies
  • Extended-release medication platforms
  • Focused ophthalmology research

DCF model

EyePoint Pharmaceuticals, Inc. (EYPT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.